The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26296911 |
11 |
3-Benzamides and 3,4,5-trimethoxyphenyl amines as calcium channel blockers. |
Ewha Womans University |
| 24205976 |
2 |
Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). |
Janssen Pharmaceutical Companies of Johnson & Johnson |
| 23876987 |
4 |
Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain. |
Abbvie |
| 23639535 |
17 |
Modular, efficient synthesis of asymmetrically substituted piperazine scaffolds as potent calcium channel blockers. |
University of British Columbia |
| 24936234 |
42 |
Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist. |
TBA |
| 23098566 |
17 |
Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain. |
Merck Research Laboratories |
| 22626552 |
2 |
Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²¿ channel blockers with analgesic activity. |
Abbott Laboratories |
| 22560585 |
16 |
Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives. |
Ajinomoto Pharmaceuticals |
| 19388676 |
21 |
Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. |
Johnson & Johnson Pharmaceutical Research & Development |
| 17483457 |
58 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. |
Abbott Laboratories |
| 15537361 |
9 |
Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain. |
Universit£ |
| 11000000 |
1 |
(S)-4-Methyl-2-(methylamino)pentanoic acid [4, 4-bis(4-fluorophenyl)butyl]amide hydrochloride, a novel calcium channel antagonist, is efficacious in several animal models of pain. |
Pfizer |
| 22177784 |
2 |
In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor. |
Kyung Hee University |
| 21316226 |
12 |
Pyridyl amides as potent inhibitors of T-type calcium channels. |
Merck Research Laboratories |
| 21195616 |
26 |
A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain. |
Merck Research Laboratories |
| 20934333 |
2 |
Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists. |
Icagen |
| 20855211 |
91 |
Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. |
Abbott Laboratories |
| 20382529 |
13 |
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers. |
Institute of Science and Technology |
| 19683451 |
12 |
Omega-conotoxin GVIA mimetics based on an anthranilamide core: effect of variation in ammonium side chain lengths and incorporation of fluorine. |
The University of Queensland |
| 19362476 |
13 |
Low molecular weight non-peptide mimics of omega-conotoxin GVIA. |
Csiro Molecular and Health Technologies |
| 17134896 |
41 |
Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. |
Ionix Pharmaceuticals |
| 16722655 |
28 |
Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. |
Pfizer |
| 12161113 |
8 |
L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models. |
Minase Research Institute |
| 11958993 |
23 |
Structure-activity study of L-cysteine-based N-type calcium channel blockers: optimization of N- and C-terminal substituents. |
Minase Research Institute |
| 11514140 |
17 |
Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers. |
No Pharmaceutical |
| 10714496 |
4 |
Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA. |
Parke-Davis Neuroscience Research Centre |
| 10514294 |
15 |
Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties. |
Warner-Lambert |
| 10476886 |
14 |
Structure-activity relationship at the proximal phenyl group in a series of non-peptidyl N-type calcium channel antagonists. |
Parke-Davis Pharmaceutical Research |
| 10476885 |
14 |
Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. |
Warner-Lambert |
| 10465535 |
14 |
Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers. |
Warner-Lambert |
| 10406647 |
30 |
Multiple parallel synthesis of N,N-dialkyldipeptidylamines as N-type calcium channel blockers. |
Warner-Lambert |
| 10328297 |
13 |
Synthesis and biological evaluation of substituted 4-(OBz)phenylalanine derivatives as novel N-type calcium channel blockers. |
Warner-Lambert |
| 10206559 |
18 |
N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. |
Warner-Lambert |
| 9873552 |
12 |
Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. |
Warner-Lambert |
| 16309909 |
54 |
Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. |
Ajinomoto |
| 30337231 |
47 |
Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Ca |
Janssen Research & Development |
| 29622412 |
64 |
Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. |
Iitb-Monash Research Academy |
| 15131245 |
86 |
SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. |
Sanofi-Synthelabo Recherche |
| 12721338 |
61 |
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. |
Pudue Pharma Discovery Research |
| 12431845 |
84 |
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. |
Eli Lilly |
| 11750180 |
139 |
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. |
Eli Lilly |
| 9454810 |
72 |
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. |
Sanofi Recherche |
| 8887981 |
72 |
A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. |
Abbott Laboratories |
| 7518514 |
46 |
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. |
Abbott Laboratories |
Search and Browse
